941 related articles for article (PubMed ID: 8382063)
21. Pharmacologic evidence for 5-HT1A receptors associated with human retinal pigment epithelial cells in culture.
Nash MS; Osborne NN
Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):510-9. PubMed ID: 9040484
[TBL] [Abstract][Full Text] [Related]
22. (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.
Schreiber R; Brocco M; Audinot V; Gobert A; Veiga S; Millan MJ
J Pharmacol Exp Ther; 1995 Apr; 273(1):101-12. PubMed ID: 7714755
[TBL] [Abstract][Full Text] [Related]
23. Stimulation and inhibition of adenylyl cyclase by distinct 5-hydroxytryptamine receptors.
De Vivo M; Maayani S
Biochem Pharmacol; 1990 Oct; 40(7):1551-8. PubMed ID: 2222510
[TBL] [Abstract][Full Text] [Related]
24. Effects of WAY 100635 and (-)-5-Me-8-OH-DPAT, a novel 5-HT1A receptor antagonist, on 8-OH-DPAT responses.
Trillat AC; Malagié I; Mathé-Allainmat M; Anmela MC; Jacquot C; Langlois M; Gardier AM
Eur J Pharmacol; 1998 Apr; 347(1):41-9. PubMed ID: 9650846
[TBL] [Abstract][Full Text] [Related]
25. Constitutive G(i2)-dependent activation of adenylyl cyclase type II by the 5-HT1A receptor. Inhibition by anxiolytic partial agonists.
Albert PR; Sajedi N; Lemonde S; Ghahremani MH
J Biol Chem; 1999 Dec; 274(50):35469-74. PubMed ID: 10585418
[TBL] [Abstract][Full Text] [Related]
26. Differential coupling of 5-HT1A receptors occupied by 5-HT or 8-OH-DPAT to adenylyl cyclase.
Varrault A; Bockaert J
Naunyn Schmiedebergs Arch Pharmacol; 1992 Oct; 346(4):367-74. PubMed ID: 1436121
[TBL] [Abstract][Full Text] [Related]
27. 8-hydroxy-2-(di-n-propylamino)tetralin-responsive 5-hydroxytryptamine4-like receptor expressed in bovine pulmonary artery smooth muscle cells.
Becker BN; Gettys TW; Middleton JP; Olsen CL; Albers FJ; Lee SL; Fanburg BL; Raymond JR
Mol Pharmacol; 1992 Nov; 42(5):817-25. PubMed ID: 1331764
[TBL] [Abstract][Full Text] [Related]
28. Contractile effects of 8-hydroxy-2-(di-n-propylamino)tetralin and flesinoxan in human isolated basilar artery.
Parsons AA; Motevalian M; Whalley ET
Eur J Pharmacol; 1991 Sep; 202(1):17-23. PubMed ID: 1664803
[TBL] [Abstract][Full Text] [Related]
29. Serotonin and the mammalian circadian system: I. In vitro phase shifts by serotonergic agonists and antagonists.
Prosser RA; Dean RR; Edgar DM; Heller HC; Miller JD
J Biol Rhythms; 1993; 8(1):1-16. PubMed ID: 8490207
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a 5-HT1B receptor on CHO cells: functional responses in the absence of radioligand binding.
Giles H; Lansdell SJ; Bolofo ML; Wilson HL; Martin GR
Br J Pharmacol; 1996 Mar; 117(6):1119-26. PubMed ID: 8882605
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological characterizations of recombinant human 5-HT1D alpha and 5-HT1D beta receptor subtypes coupled to adenylate cyclase inhibition in clonal cell lines: apparent differences in drug intrinsic efficacies between human 5-HT1D subtypes.
Zgombick JM; Schechter LE; Adham N; Kucharewicz SA; Weinshank RL; Branchek TA
Naunyn Schmiedebergs Arch Pharmacol; 1996; 354(3):226-36. PubMed ID: 8878051
[TBL] [Abstract][Full Text] [Related]
32. Antagonism of 5-hydroxytryptamine1A (5-HT1A) receptor-mediated modulation of adenylate cyclase activity by pindolol and propranolol isomers.
Oksenberg D; Peroutka SJ
Biochem Pharmacol; 1988 Sep; 37(18):3429-33. PubMed ID: 2971358
[TBL] [Abstract][Full Text] [Related]
33. Serotonin inhibits adenylate cyclase in human platelet membranes.
Newman ME
Eur J Pharmacol; 1992 Aug; 226(4):281-5. PubMed ID: 1397059
[TBL] [Abstract][Full Text] [Related]
34. Nad-299 antagonises 5-HT-stimulated and spiperone-inhibited [35S]GTPgammaS binding in cloned 5-HT1A receptors.
Jerning E; Rosqvist S; Mohell N
J Recept Signal Transduct Res; 2002; 22(1-4):483-95. PubMed ID: 12503636
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological profile of (-)HT-90B, a novel 5-HT1A receptor agonist/5-HT2 receptor antagonist.
Uchida H; Inagawa K; Tameda C; Miyauchi T
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Nov; 19(7):1201-16. PubMed ID: 8787043
[TBL] [Abstract][Full Text] [Related]
36. Further assessment of the antagonist properties of the novel and selective 5-HT1A receptor ligands (+)-WAY 100 135 and SDZ 216-525.
Lanfumey L; Haj-Dahmane S; Hamon M
Eur J Pharmacol; 1993 Nov; 249(1):25-35. PubMed ID: 8282017
[TBL] [Abstract][Full Text] [Related]
37. Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
Adham N; Kao HT; Schecter LE; Bard J; Olsen M; Urquhart D; Durkin M; Hartig PR; Weinshank RL; Branchek TA
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):408-12. PubMed ID: 8380639
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological characterization of two 5-hydroxytryptamine receptors coupled to adenylate cyclase in guinea pig hippocampal membranes.
Shenker A; Maayani S; Weinstein H; Green JP
Mol Pharmacol; 1987 Apr; 31(4):357-67. PubMed ID: 2952874
[TBL] [Abstract][Full Text] [Related]
39. Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors.
Oz M; Zhang L; Rotondo A; Sun H; Morales M
Synapse; 2003 Dec; 50(4):303-13. PubMed ID: 14556235
[TBL] [Abstract][Full Text] [Related]
40. The 5-hydroxytryptamine 5-HT1D receptor subtype is negatively coupled to adenylate cyclase in calf substantia nigra.
Schoeffter P; Waeber C; Palacios JM; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1988 Jun; 337(6):602-8. PubMed ID: 3216894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
